Integrative fragmentomic and mutational signature profile of plasma cfDNA for early lung cancer detection - PubMed
4 hours ago
- #biomarkers
- #cancer screening
- #liquid biopsy
- Study developed a blood-based multi-omics model using cfDNA fragmentomic and mutational signatures for early lung cancer detection.
- Model achieved high AUC (95.59% training, 95.74% validation) and performed well across stages and subtypes.
- External validation showed 85.9% sensitivity and 94.78% specificity, outperforming LDCT in simulated screenings.
- Assay has potential as a complementary tool in wider screening programs, offering high sensitivity and non-invasive detection.